Tomivosertib
Tomivosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against MAP kinase-interacting serine/threonine-protein kinase 2 and MAP kinase-interacting serine/threonine-protein kinase 1. In addition, it is known to target serine/threonine-protein kinase 17A and dual specificity protein kinase CLK4.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TOMIVOSERTIB |
INN | tomivosertib |
Description | Tomivosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against MAP kinase-interacting serine/threonine-protein kinase 2 and MAP kinase-interacting serine/threonine-protein kinase 1. In addition, it is known to target serine/threonine-protein kinase 17A and dual specificity protein kinase CLK4. |
Classification | Small molecule |
Drug class | serine/threonine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1 |
Identifiers
PDB | — |
CAS-ID | 1849590-01-7 |
RxCUI | — |
ChEMBL ID | CHEMBL4073443 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | U2H19X4WBV (ChemIDplus, GSRS) |
Target
Agency Approved
MKNK2
MKNK2
MKNK1
MKNK1
Organism
Homo sapiens
Gene name
MKNK2
Gene synonyms
GPRK7, MNK2
NCBI Gene ID
Protein name
MAP kinase-interacting serine/threonine-protein kinase 2
Protein synonyms
G protein-coupled receptor kinase 7, MAP kinase interacting serine/threonine kinase 2, MAP kinase signal-integrating kinase 2, MAPK signal-integrating kinase 2, Mnk2
Uniprot ID
Mouse ortholog
Mknk2 (17347)
MAP kinase-interacting serine/threonine-protein kinase 2 (Q9D893)
Alternate
STK17A
STK17A
CLK4
CLK4
Organism
Homo sapiens
Gene name
STK17A
Gene synonyms
DRAK1
NCBI Gene ID
Protein name
serine/threonine-protein kinase 17A
Protein synonyms
DAP kinase-related apoptosis-inducing protein kinase 1, death-associated protein kinase-related 1, serine/threonine kinase 17a (apoptosis-inducing)
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 81 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,178 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more